Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting

被引：4

作者：

Rocabert, Alba ^{[1
]}

Borjabad, Beatriz ^{[2
]}

Berrocal, Leire ^{[1
]}

Blanch, Jordi ^{[1
]}

Inciarte, Alexy ^{[1
]}

Chivite, Ivan ^{[1
]}

Gonzalez-Cordon, Ana ^{[1
]}

Torres, Berta ^{[1
]}

Ambrosioni, Juan ^{[1
,3
]}

Martinez-Rebollar, Maria ^{[1
,3
]}

Laguno, Montserrat ^{[1
,3
]}

De La Mora, Lorena ^{[1
]}

Foncillas, Alberto ^{[1
]}

Sempere, Abiu ^{[1
]}

Rodriguez, Ana ^{[1
]}

Solbes, Estela ^{[1
]}

Llobet, Roger ^{[1
]}

Miro, Jose M. ^{[1
,3
]}

Mallolas, Josep ^{[1
,3
]}

Blanco, Jose L. ^{[1
,3
]}

De Lazzari, Elisa ^{[1
,3
]}

Martinez, Esteban ^{[1
,3
]}

机构：

[1] Univ Barcelona, Hosp Clin, Barcelona, Spain

[2] Hosp Moises Broggi, Serv Internal Med, Sant Joan Despi, Spain

[3] Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERINFEC, Madrid, Spain

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2023年 / 78卷 / 12期

关键词：

TENOFOVIR DISOPROXIL FUMARATE; ALAFENAMIDE; HIV; INFECTION; ADULTS;

D O I：

10.1093/jac/dkad338

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background While both the burden of therapy and the individual drugs in bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir/lamivudine differ, it is unclear whether their real-life tolerability may be also different.Methods Single-centre, clinical cohort analysis of all virologically suppressed persons with HIV (PWH) who were first prescribed bictegravir as BIC/TAF/FTC or dolutegravir as dolutegravir/lamivudine and had taken >= 1 dose of study medication. Major outcomes were discontinuations either for any reason or due to toxicity. Incidence was calculated as number of episodes per 100 person-years adjusted through propensity score analysis.Results Relative to persons treated with BIC/TAF/FTC (n = 1231), persons treated with dolutegravir/lamivudine (n = 821) were older and had more AIDS-defining conditions although better HIV control. After a median follow-up of 52 weeks, adjusted incidence rates for discontinuation were 6.68 (95% CI 5.18-8.19) and 8.44 (95% CI 6.29-10.60) episodes per 100 person-years for BIC/TAF/FTC and dolutegravir/lamivudine, respectively; adjusted incidence rate ratio for dolutegravir/lamivudine was 1.26 (95% CI 0.89-1.78) relative to BIC/TAF/FTC (P = 0.1847). Adjusted incidence rates for discontinuation due to toxicity were 3.88 (95% CI 2.70-5.06) and 4.62 (95% CI 3.05-6.19) episodes per 100 person-years for BIC/TAF/FTC and dolutegravir/lamivudine, respectively; adjusted incidence rate ratio for dolutegravir/lamivudine was 1.19 (95% CI 0.75-1.90) relative to BIC/TAF/FTC (P = 0. 4620). Adverse events leading to discontinuation were neuropsychiatric (n = 42; 2%), followed by gastrointestinal (n = 23; 1%), dermatological (n = 15; 1%) and weight increase (n = 15; 1%), without differences between regimens.Conclusions Switching to BIC/TAF/FTC or dolutegravir/lamivudine showed no difference in the risks of overall or toxicity-related discontinuations or in the profile of adverse events leading to discontinuation.

引用

页码：2961 / 2967

页数：7

共 33 条

[21] Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review [J].

Perez-Valero, Ignacio ;

Corona, Diana ;

Martinez, Natalia ;

Lopez-Cavanillas, Maria ;

Lluis, Carla ;

Luque, Isabel .

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (06) :655-665

[22]

Rojas J, 2021, LANCET HIV, V8, pE463, DOI 10.1016/S2352-3018(21)00100-4

[23]

Sax P., 2023, 30 C RETR OPP INF

[24] Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials [J].

Sax, Paul E. ;

Erlandson, Kristine M. ;

Lake, Jordan E. ;

Mccomsey, Grace A. ;

Orkin, Chloe ;

Esser, Stefan ;

Brown, Todd T. ;

Rockstroh, Jurgen K. ;

Wei, Xuelian ;

Carter, Christoph C. ;

Zhong, Lijie ;

Brainard, Diana M. ;

Melbourne, Kathleen ;

Das, Moupali ;

Stellbrink, Hans-Jurgen ;

Post, Frank A. ;

Waters, Laura ;

Koethe, John R. .

CLINICAL INFECTIOUS DISEASES, 2020, 71 (06) :1379-1389

[25] HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety [J].

Scarsi, Kimberly K. ;

Havens, Joshua P. ;

Podany, Anthony T. ;

Avedissian, Sean N. ;

Fletcher, Courtney, V .

DRUGS, 2020, 80 (16) :1649-1676

[26] Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir [J].

Squillace, Nicola ;

Ricci, Elena ;

Maggi, Paolo ;

Taramasso, Lucia ;

Menzaghi, Barbara ;

De Socio, Giuseppe Vittorio ;

Piconi, Stefania ;

Maurizio Celesia, Benedetto ;

Orofino, Giancarlo ;

Sarchi, Eleonora ;

Pellicano, Giovanni Francesco ;

Simeone, Filomena ;

Valsecchi, Laura ;

Bandera, Alessandra ;

Cenderello, Giovanni ;

Attala, Letizia ;

Angioni, Goffredo ;

Falasca, Katia ;

Cascio, Antonio ;

Bargiacchi, Olivia ;

Di Biagio, Antonio ;

Bonfanti, Paolo .

PLOS ONE, 2023, 18 (08)

[27] Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV A Cohort Study [J].

Surial, Bernard ;

Mugglin, Catrina ;

Calmy, Alexandra ;

Cavassini, Matthias ;

Gunthard, Huldrych F. ;

Stockle, Marcel ;

Bernasconi, Enos ;

Schmid, Patrick ;

Tarr, Philip E. ;

Furrer, Hansjakob ;

Ledergerber, Bruno ;

Wandeler, Gilles ;

Rauch, Andri .

ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) :758-+

[28] ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA < 500 000 Copies/mL [J].

Taiwo, Babafemi O. ;

Zheng, Lu ;

Stefanescu, Andrei ;

Nyaku, Amesika ;

Bezins, Baiba ;

Wallis, Carole L. ;

Godfrey, Catherine ;

Sax, Paul E. ;

Acosta, Edward ;

Haas, David ;

Smith, Kimberly Y. ;

Sha, Beverly ;

Van Dam, Cornelius ;

Gulic, Roy M. .

CLINICAL INFECTIOUS DISEASES, 2018, 66 (11) :1689-1697

[29]

UNAIDS, 2021, UNAIDS DAT

[30]

van Wyk J, 2021, JAIDS-J ACQ IMM DEF, V87, P794, DOI 10.1097/QAI.0000000000002655

← 1 2 3 4 →